Literature DB >> 19563448

Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis.

Johannes A A Meijer1, Saskia le Cessie, Wilbert B van den Hout, Job Kievit, Johannes W Schoones, Johannes A Romijn, Johannes W A Smit.   

Abstract

CONTEXT: In the management of patients with medullary thyroid carcinoma (MTC), calcitonin doubling time (dt) has gained interest as an independent predictor of recurrence and survival.
OBJECTIVE: To perform a structured meta-analysis of the diagnostic value of calcitonin dt, carcinoembryonic antigen (CEA) dt and the combination and to define dt strata with the highest predictive power. Design The study was a meta-analysis using individual data.
METHODS: Ten studies containing data on the post-operative kinetics of tumour marker(s) and (recurrence free) survival were included.
RESULTS: Calcitonin- and CEA-dt are significant indicators for survival (hazard ratios (HR) 21.52 respectively infinite for dt 0-1 year compared to dt >1 year) and recurrence (HR 5.33 respectively 6.80 for dt 0-1 year compared to dt >1 year). The highest predictive power was found for the dt classification 0-1 year vs. >1 year. CEA dt has a higher predictive value than calcitonin dt in the subgroup of patients for which both parameters were available.
CONCLUSION: The dts of both calcitonin and CEA are strong prognostic indicators for MTC recurrence and death. CEA dt has a higher predictive value than calcitonin dt and therefore measuring both tumour markers is essential for proper risk stratification.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563448     DOI: 10.1111/j.1365-2265.2009.03666.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  35 in total

1.  Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer.

Authors:  Allen S Ho; Lu Wang; Frank L Palmer; Changhong Yu; Arnbjorn Toset; Snehal Patel; Michael W Kattan; R Michael Tuttle; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2014-11-04       Impact factor: 5.344

2.  Esophageal recurrence of medullary thyroid carcinoma.

Authors:  Jose Luis Muñoz de Nova; Agnieszka Dworzynska; Leyre Lorente-Poch; Juan Jose Sancho; Antonio Sitges-Serra
Journal:  Gland Surg       Date:  2015-12

3.  Treating medullary thyroid cancer in the age of targeted therapy.

Authors:  Maria E Cabanillas; Mimi I Hu; Camilo Jimenez; Elizabeth G Grubbs; Gilbert J Cote
Journal:  Int J Endocr Oncol       Date:  2014

Review 4.  Calcitonin as a biomarker of C cell disease: recent achievements and current challenges.

Authors:  Giuseppe Costante; Domenico Meringolo
Journal:  Endocrine       Date:  2020-01-10       Impact factor: 3.633

Review 5.  Advances in the follow-up of differentiated or medullary thyroid cancer.

Authors:  Rossella Elisei; Aldo Pinchera
Journal:  Nat Rev Endocrinol       Date:  2012-04-03       Impact factor: 43.330

6.  Medullary carcinoma of the thyroid with axillary metastasis: a case report.

Authors:  Murat Ozdemir; Ozer Makay; Ilgin Simsir; Yeşim Ertan; Gokhan Icoz; Füsun Saygili; Mahir Akyildiz
Journal:  Int Surg       Date:  2015-03

7.  Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.

Authors:  Gilbert J Cote; Caitlin Evers; Mimi I Hu; Elizabeth G Grubbs; Michelle D Williams; Tao Hai; Dzifa Y Duose; Michal R Houston; Jacquelin H Bui; Meenakshi Mehrotra; Steven G Waguespack; Naifa L Busaidy; Maria E Cabanillas; Mouhammed Amir Habra; Rajyalakshmi Luthra; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

8.  Measurement of calcitonin and calcitonin gene-related peptide mRNA refines the management of patients with medullary thyroid cancer and may replace calcitonin-stimulation tests.

Authors:  Cléber P Camacho; Susan C Lindsey; Maria Clara C Melo; Ji H Yang; Fausto Germano-Neto; Flávia de O F Valente; Thiago R N Lima; Rosa Paula M Biscolla; José G H Vieira; Janete M Cerutti; Magnus R Dias-da-Silva; Rui M B Maciel
Journal:  Thyroid       Date:  2013-03       Impact factor: 6.568

9.  ¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.

Authors:  Pierre-Yves Salaun; Loïc Campion; Catherine Ansquer; Eric Frampas; Cédric Mathieu; Philippe Robin; Claire Bournaud; Jean-Philippe Vuillez; David Taieb; Caroline Rousseau; Delphine Drui; Eric Mirallié; Françoise Borson-Chazot; David M Goldenberg; Jean-François Chatal; Jacques Barbet; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-08       Impact factor: 9.236

10.  The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report.

Authors:  Tomasz Gawlik; Andrea d'Amico; Sylwia Szpak-Ulczok; Aleksander Skoczylas; Elżbieta Gubała; Anna Chorąży; Kamil Gorczewski; Jan Włoch; Barbara Jarząb
Journal:  Thyroid Res       Date:  2010-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.